<DOC>
	<DOCNO>NCT00646802</DOCNO>
	<brief_summary>Eligible patient inform ask enroll study hospital admission . A transvaginal ultrasound examination perform determine cervical length . If eligible woman accept participate , patient randomize one study arm assign double blind basis . Patient receive medication ( vaginal capsule progesterone placebo ) . The patient administer one vaginal capsule daily basis since gestational age 36 week 6 day primary endpoint demonstrate use maintenance treatment vaginal progesterone able reduce incidence preterm birth 34.0 37.0 gestational week . After delivery , perinatal neonatal data collect .</brief_summary>
	<brief_title>Vaginal PROgesterone Maintenance Treatment After epISode prEterm Labor ( PROMISE Study )</brief_title>
	<detailed_description />
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Pregnant woman age 18 45 year Gestational age 24.0 33.6 gestational week Singleton pregnancy Patients admit preterm labor successfully treat tocolytic drug ( Î²mimetics drug , nifedipine , atosiban ) Ultrasound cervical length discharge &lt; 25 mm Signed patient consent form ( CI ) Known suspected infection , premature rupture membrane pathological gravid maternal fetal condition coexist hospital admission ( Preeclampsia , RCIU ) may induce iatrogenic labor . Present previous liver disease , present previous cholestasis gravidarum , abnormal hepatic blood test . With known allergy progesterone peanut ( excipient ) . Grade 2 ( upper ) renal liver laboratory abnormality Treated dependenthormone malignant cancer ( i.e. , breast carcinoma ... ) With Diabetes mellitus insulinized gestational diabetes Treated heparin Drug abuse Inadequate treatment compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>